NCT05031949 2023-12-19
CCGLC-003
Tongji Hospital
Phase 1 Unknown
Clinical Trials
10 trialsNCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT04932187 2021-09-17
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
Ruijin Hospital
Phase 1 Unknown
NCT05008861 2021-08-17
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT05001412 2021-08-12
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT04508686 2021-01-29
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
Ruijin Hospital
Phase 1 Unknown
NCT04625894 2020-11-12
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer
Fudan University
Phase 1 Unknown
NCT04510818 2020-08-14
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
Ruijin Hospital
Phase 1 Unknown
NCT03393416 2019-08-29
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
HRYZ Biotech Co.
Phase 1 Unknown
NCT03527251 2018-05-30
SEQUENCE
Sun Yat-sen University
Phase 1 Unknown